Industry News
Hemacord - First Cord Blood Product Approved By FDA
Nov 12, 2011
The FDA has approved HEMACORD, the first cord blood product ever to be approved in the USA. It used in hematopoietic stem cell transplantation procedures for individuals with disorders affecting the blood-forming system - known as the hematopoietic system. Potential patients include those with some kinds of blood cancers, as well as people with inherited metabolic and immune system disorders... Read More
FDA Approves New York Blood Center's HEMACORD™ For Stem Cell Transplantation
Nov 12, 2011
The Food and Drug Administration has licensed HEMACORD™ (Hematopoietic Progenitor Cells-Cord, HPC-C) for allogeneic hematopoietic (blood-forming) stem cell transplantation, the first such approval of a stem cell product in the world... Read More
Predicting Cellular Response To Paclitaxel In Epithelial Ovarian Cancer
Nov 12, 2011
New research findings by UCD scientists published online today in the Journal of Pathology may help clinicians predict how patients with high grade, serous, epithelial ovarian cancer will respond to paclitaxel chemotherapy (Taxol®)... Read More
High Fiber Diet Reduces Colorectal Cancer Risk
Nov 12, 2011
A new study published on bmj.com demonstrates that eating high- fiber diet, particularly cereal and whole grains, is linked to a reduced risk of colorectal cancer. Worldwide, colorectal cancer is the third most common cancer, with 1.2 million new cases diagnosed every year... Read More
Fibre, Whole Grains, Linked To Lower Colorectal Cancer Risk
Nov 11, 2011
Following a diet high in fibre, particularly from whole grains and cereals like brown rice and oats, is linked to a lower risk of colorectal cancer, according to researchers in Britain and The Netherlands who pooled all available published evidence, covering nearly 2 million people. They write about their findings in a study published online in the BMJ on 10 November... Read More
FDA Approves Cord Blood For Stem Cell Transplant
Nov 11, 2011
The US Food and Drug Administration (FDA) has approved the first product to use umbilical cord blood for stem cell transplantation. In a news release on Thursday, the agency said it has approved Hemacord, developed by the New York Blood Center, as "the first licensed hematopoietic progenitor cells-cord (HPC-C) cell therapy"... Read More
Drug That Attacks Blood Supply Of Fat Cells Causes Weight Loss In Obese Monkeys
Nov 11, 2011
Obese rhesus monkeys lost on average 11 percent of their body weight after four weeks of treatment with an experimental drug that selectively destroys the blood supply of fat tissue, a research team led by scientists at The University of Texas MD Anderson Cancer Center reports in Science Translational Medicine... Read More
Fecal Occult Blood Testing Effective In Colonoscopy Screenings
Nov 11, 2011
Fecal immunochemical testing (FIT) is more effective in its health benefits at the same or lower costs compared to guaiac fecal occult blood testing (gFOBT) at all levels of colonoscopy capacity, according to a study published by the Journal of the National Cancer Institute. In many countries, wait times for colonoscopy screenings can take up to 12 weeks... Read More
Colonoscopy Screenings - Fecal Occult Blood Testing Effective
Nov 10, 2011
According to an investigation published on November, 9 by the Journal of the National Cancer Institute, researchers have discovered that the health benefits of fecal immunochemical testing (FIT) is more effective than guaiac fecal occult blood testing (gFOBT) at equal or lower costs at all levels of colonoscopy capacity... Read More
HPV Vaccine Might Lower Cervical Cancer Rate Considerably - Screening Programs Should Be Changed
Nov 10, 2011
According to findings of two investigations published Online First in The Lancet Oncology, the bivalent human papillomavirus (HPV) vaccine (GlaxoSmithKline, Cervarix) provides exceptional protection against the more serious immediate precursor to invasive cervical cancer (ICC). It is particularly effective in protecting young girls prior to becoming sexually active... Read More
Previous Page Next Page